|
|
 |
|
Viewing report
|
|
|
|
The Antivirals Pipeline: Competitive Review
Decision Resources, Inc., May 2010, Pages: 22
Although the market is already crowded, antiviral agents that can treat diseases such as HIV and hepatitis C virus (HCV) can still expect success. This potential for success is only one of the reasons that 122 companies are actively involved in clinical development of 139 antiviral agents despite the plethora of available agents. Given the need for therapies that can deal with mutating viruses that render current therapies ineffective and for therapies that can treat the side effects that plague patients on long-term antiviral therapy (among other unmet needs), the antivirals market is still an attractive market for drug developers despite various obstacles that are challenging market growth.
Questions Answered in this Report:
- The antivirals market has grown steadily since 2004 and, excepting a less robust period from 2009 to 2010, is expected to continue this steady growth. What forces and trends are driving this growth? What situations will impact sales growth from 2009 to 2010?
- Although a multitude of effective therapies are available to treat indications such as HIV and HCV, unmet needs are still driving significant clinical development in the antivirals pipeline. What are the various unmet needs in HIV, HCV, and other indications? How many antivirals are in development for HIV and HCV, and how can these therapies be classified?
- Both current and emerging market-leading companies will drive the growth of the antivirals market. Which companies are the current market leaders, and which companies are projected to be the market leaders in 2015? Which companies are attempting to establish, grow, or protect their position in this market? Which indications and drug classes will drive most of the growth?
Scope:
- The antivirals pipeline: Number of agents in development; disease focus; NMEs versus reformulations; formulations by disease; drug targets; small-molecule drugs versus biologics; phase analysis; development by company type; number of agents by phase; number of agents by disease; profiles of GlaxoSmithKline, Pfizer, Viiv Healthcare, and Gilead Sciences.
- Historical and projected antiviral sales: 2004-2015 sales; leading drug classes; current and projected market-leading companies; key patent expiries impacting antiviral sales; R&D spend of market-leading companies.
- Market opportunities/drivers: Oral HCV therapies; drugs to treat mutated HIV viruses and patients who develop long-term side effects from current therapies; antivirals with increased efficacy; better tests to identify mutated viruses and diagnose patients.
- Market constraints: Lack of a “universal” antiviral to treat multiple viral infections; generics.
- Markets covered: United States, rest of world.
- Primary research: Insight from a survey of 100 U.S. board-certified infectious disease specialists.
- Data-rich content: 27 tables and figures that detail our pipeline and market findings.
Key Terms for this Report:
Antivirals, Antivirals market, Antivirals pipeline, Antivirals sales forecast, HCV, Hepatitis C, HIV, Influenza, NRTI, NNRTI, Nucleoside analogue, Protease inhibitor, RSV, Viral resistance, Viral mutation
Customers who bought this item also bought
Antivirals: Novel Targets, Technologies, and Dealmaking
Dealmaking and Industry Outlook: Antivirals
Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?
The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape
Antivirals - Global Strategic Business Report
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
The Neurology Pipeline: A Strategic Review
Competitor Analysis: Targeted Therapy of Hepatitis C
How to Enhance the Value of Antiviral Therapies through Biomarkers and Diagnostics
|
|
|
|
